# Assignment 5 Emerging Technology Diffusion Agent Record

## A. Agent and version

| Field | Student record |
| --- | --- |
| Student / team | Repository owner: `yicrry777`; personal name not supplied |
| Assignment / specialist agent | Week 7, Assignment 5 / Emerging Technology Diffusion Agent |
| Date | 2026-10-24, America/New_York |
| GitHub repository | https://github.com/yicrry777/1800lab5 |
| Branch | `codex/assignment-5-diffusion` |
| Tested candidate commit | `ca60af61baf9af36f9be6768ac11045ad7b29b36` |
| Frozen scaffold version | MASY1800_ET_Agent_Scaffold_v1_0; frozen-core integrity check passed |
| Agent version | `0.2-student` |

## B. Context

| Field | Student record |
| --- | --- |
| Emerging technology | Generative-AI ambient clinical scribing |
| Intended application | Draft outpatient primary-care visit notes from conversations, with clinician review before signing |
| Organization / industry | Hypothetical 40-clinician U.S. safety-net outpatient network / ambulatory primary care |
| Adoption posture | Conservative, risk-averse follower |
| Risk / consequence context | Note errors and omissions, patient consent and privacy, multilingual performance, trust; clinician retains final authority |
| Management question / time horizon | When to evaluate a bounded pilot over the next 12 months, without deciding on full adoption |

## C. Three-level finding

| Field | Student record |
| --- | --- |
| ET generally | Large U.S. academic systems have deployed ambient scribes, but supplied sources lack a representative ambient-scribe denominator. National adopter category is indeterminate. AMA's 81% broad-AI figure is not ambient-scribe prevalence. |
| ET for this application | Outpatient note drafting has demonstrated use and possible note-time benefit. Relative advantage is plausible; EHR/device fit, clinician review, consent and training affect compatibility and complexity. A small pilot is trialable; note share, corrections, time and feedback are observable. Primary-care peer penetration is unknown. |
| ET for this application in this organization | Limited IT, mixed devices, unresolved privacy/EHR review and multilingual needs make the same external evidence less sufficient for a near-term live pilot. Local compatibility and validation capacity are the main inhibitors. |
| Bounded management implication | Start readiness work now; consider a small opt-in pilot in roughly 6–12 months only if privacy, consent, EHR, clinician review and language-quality gates are met. The specialist makes no purchase or system-wide adoption decision. |
| Confidence / uncertainty | Moderate for feasibility in selected well-resourced systems, low for national stage, safety-net peer diffusion and local benefit. Scenario organization is hypothetical. |
| Evidence or condition that changes conclusion | Representative peer active-use/note-share data; completed local integration and privacy review; acceptable stratified note-quality and time measures; workable training capacity. |

## D. Evidence and testing

| Field | Student record |
| --- | --- |
| Most important evidence / sources | [AMA 2026 physician survey](https://www.ama-assn.org/sites/ama-assn.org/files/2026-03/physician-ai-sentiment-report_0.pdf); [Vanderbilt rollout case](https://academic.oup.com/jamia/article/33/2/457/8307782); [Afshar randomized implementation](https://pmc.ncbi.nlm.nih.gov/articles/PMC12858090/). Dates, denominators and limits are in [the evidence and test record](test_and_evidence_record.md). |
| Primary test result | Prompt built; saved structured output passed supplied validator. Conservative safety-net timing: readiness now, conditional pilot in roughly 6–12 months. |
| Contrast test — what stayed stable | Same general technology finding, application factor assessment and external evidence across both aggressive and moderate contrasts; national diffusion stage remains indeterminate. |
| Contrast test — what changed | Academic early adopter can consider a controlled pilot in 0–3 months; fast follower in 3–6 months after peer/local checks; safety-net network in 6–12 months after more gates. |
| Weakness / failure found | v0.1 output inferred U.S. “early majority” from AMA broad-AI use and one hospital rollout, despite incompatible denominators. The JSON validator passed this content error. |
| Revision made and why | v0.2 requires population, geography, date and use measure; separates market stage from organization posture; requires explicit abstention when adoption-rate evidence is missing. |
| Remaining limitation / abstention | No representative U.S. or safety-net primary-care ambient-scribe adoption series. Do not assign market stage or promise local time savings. |

## E. Independent judgment and handoff

**Credibility for team consideration.** Yes, for a bounded timing discussion. The revised output preserves general evidence across contrasting organizations and changes management timing for stated reasons. It should be rerun with real organizational facts and current sources before operational use.

**Most important recommendation.** Carry forward successful deployment and measurable note use at Vanderbilt as the strongest observed diffusion signal, local compatibility/validation as the most important inhibitor, and the conditional safety-net pilot window. The Adoption Agent should inherit the missing peer denominator and require local quality, privacy, cost and workflow evidence before a full decision.

**AI / verification note.** ChatGPT/Codex helped map Rogers' factors, draft the specialist instructions, create contrasting cases, produce representative structured responses and diagnose the stage error. Consequential adoption and benefit claims were checked against the original AMA survey and original research reports. The common validator, contrast check and frozen-core checker were actually run; command results are recorded in [the evidence and test record](test_and_evidence_record.md). No live clinical data or external model API was used.
